Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat

This article was originally published in The Pink Sheet Daily

Executive Summary

Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.
Advertisement

Related Content

Cell Therapeutics’ Tosedostat Gets Back On Track
Cell Therapeutics’ Tosedostat Gets Back On Track
Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says
Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says
ODAC Sides With FDA: Evidence For Elderly AML Drugs Can't Stand On Single-Arm Trials
UK's Chroma and GlaxoSmithKline Target Macrophages For Anti-Inflammatory UseI

Topics

Advertisement
UsernamePublicRestriction

Register

PS071948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel